Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.

Zsebo K, Yaroshinsky A, Rudy JJ, Wagner K, Greenberg B, Jessup M, Hajjar RJ.

Circ Res. 2014 Jan 3;114(1):101-8. doi: 10.1161/CIRCRESAHA.113.302421. Epub 2013 Sep 24.

2.

Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.

Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Desai AS, Barnard D, Bouchard A, Jaski B, Lyon AR, Pogoda JM, Rudy JJ, Zsebo KM.

Lancet. 2016 Mar 19;387(10024):1178-86. doi: 10.1016/S0140-6736(16)00082-9. Epub 2016 Jan 21.

PMID:
26803443
3.

Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).

Greenberg B, Yaroshinsky A, Zsebo KM, Butler J, Felker GM, Voors AA, Rudy JJ, Wagner K, Hajjar RJ.

JACC Heart Fail. 2014 Feb;2(1):84-92. doi: 10.1016/j.jchf.2013.09.008. Epub 2014 Jan 25.

PMID:
24622121
4.

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators.

Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27.

5.

Gene therapy for heart failure.

Greenberg B.

J Cardiol. 2015 Sep;66(3):195-200. doi: 10.1016/j.jjcc.2015.02.006. Epub 2015 Mar 25. Review.

6.

Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.

Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, Ly H, Kawase Y, Wagner K, Borow K, Jaski B, London B, Greenberg B, Pauly DF, Patten R, Starling R, Mancini D, Jessup M.

J Card Fail. 2008 Jun;14(5):355-67. doi: 10.1016/j.cardfail.2008.02.005. Epub 2008 May 27.

PMID:
18514926
7.

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators.

J Card Fail. 2009 Apr;15(3):171-81. doi: 10.1016/j.cardfail.2009.01.013.

8.

Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.

Hulot JS, Salem JE, Redheuil A, Collet JP, Varnous S, Jourdain P, Logeart D, Gandjbakhch E, Bernard C, Hatem SN, Isnard R, Cluzel P, Le Feuvre C, Leprince P, Hammoudi N, Lemoine FM, Klatzmann D, Vicaut E, Komajda M, Montalescot G, Lompré AM, Hajjar RJ; AGENT-HF Investigators.

Eur J Heart Fail. 2017 Apr 10. doi: 10.1002/ejhf.826. [Epub ahead of print]

PMID:
28393439
9.

Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.

Greenberg B, Butler J, Felker GM, Ponikowski P, Voors AA, Pogoda JM, Provost R, Guerrero J, Hajjar RJ, Zsebo KM.

Gene Ther. 2016 Mar;23(3):313-9. doi: 10.1038/gt.2015.109. Epub 2015 Dec 24.

PMID:
26699914
10.

Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.

Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ.

J Am Coll Cardiol. 2008 Mar 18;51(11):1112-9. doi: 10.1016/j.jacc.2007.12.014.

11.

Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.

Lipskaia L, Hadri L, Lopez JJ, Hajjar RJ, Bobe R.

Curr Vasc Pharmacol. 2013 Jul;11(4):465-79. Review.

PMID:
23905641
12.

Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts.

Karakikes I, Hadri L, Rapti K, Ladage D, Ishikawa K, Tilemann L, Yi GH, Morel C, Gwathmey JK, Zsebo K, Weber T, Kawase Y, Hajjar RJ.

Mol Ther. 2012 Mar;20(3):565-71. doi: 10.1038/mt.2011.268. Epub 2012 Jan 3.

13.

Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure.

del Monte F, Williams E, Lebeche D, Schmidt U, Rosenzweig A, Gwathmey JK, Lewandowski ED, Hajjar RJ.

Circulation. 2001 Sep 18;104(12):1424-9.

14.

Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.

Gwathmey JK, Yerevanian A, Hajjar RJ.

Hum Gene Ther. 2013 Nov;24(11):937-47. doi: 10.1089/hum.2013.2512. Review.

15.

Effect of SERCA2a overexpression in the pericardium mediated by the AAV1 gene transfer on rapid atrial pacing in rabbits.

Kuken BN, Aikemu AN, Xiang SY, Wulasihan MH.

Genet Mol Res. 2015 Oct 29;14(4):13625-32. doi: 10.4238/2015.October.28.24.

16.

[Adeno-associated viral gene transfer of SERCA2a improves heart function in chronic congestive heart failure rats].

Hui HP, Li XY, Liu XH, Sun S, Lu XC, Liu T, Yang W.

Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Apr;34(4):357-62. Chinese.

PMID:
16776934
17.

Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals.

Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM.

Gene Ther. 2008 Dec;15(23):1550-7. doi: 10.1038/gt.2008.120. Epub 2008 Jul 24.

PMID:
18650850
18.

SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure.

Tilemann L, Lee A, Ishikawa K, Aguero J, Rapti K, Santos-Gallego C, Kohlbrenner E, Fish KM, Kho C, Hajjar RJ.

Sci Transl Med. 2013 Nov 13;5(211):211ra159. doi: 10.1126/scitranslmed.3006487.

19.

Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.

Penny WF, Hammond HK.

Hum Gene Ther. 2017 May;28(5):378-384. doi: 10.1089/hum.2016.166. Epub 2017 Mar 16.

20.

Improvement in cardiac function after sarcoplasmic reticulum Ca2+-ATPase gene transfer in a beagle heart failure model.

Mi YF, Li XY, Tang LJ, Lu XC, Fu ZQ, Ye WH.

Chin Med J (Engl). 2009 Jun 20;122(12):1423-8.

PMID:
19567165

Supplemental Content

Support Center